Patient-Reported Outcomes — Lapuerta Consulting

Direct patient feedback provides critical information on disease impact and treatment response. The FDA has cited Dr. Lapuerta’s work with one-on-one exit interviews as a successfully implemented strategy in helping to determine meaningful change.

Improvement in Patient-Reported Outcomes in Adults with Type 1 Diabetes Treated with Sotagliflozin plus Insulin Versus Insulin Alone
Published December 31, 2020 in Diabetes Technology & Therapeutics
Clinical Benefits of Telotristat Ethyl in Patients With Neuroendocrine Tumors and Low Bowel Movement Frequency: An Observational Patient-Reported Outcomes Study
Published March 1, 2020 in Pancreas
Insights Into Patients' Experience With Type 1 Diabetes: Exit Interviews From Phase III Studies of Sotagliflozin
Published November 1, 2019 in Clinical Therapeutics
Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl
Published November 1, 2017 in Clinical Therapeutics
Patient-reported Symptom Experiences in Patients With Carcinoid Syndrome After Participation in a Study of Telotristat Etiprate: A Qualitative Interview Approach
Published March 31, 2016 in Clinical Therapeutics
Assessing Treatment Benefit of Telotristat Etiprate in Patients With Carcinoid Syndrome: Patient Exit Interviews
Presented October 16-17, 2015 at the 8th Symposium of the North American Neuroendocrine Tumor Society